Toxin News and Research

RSS

Medical Nutrition launches Diff-Stat pre- and probiotic supplement to prevent the onset of AAD and C-diff

Medical Nutrition USA, Inc., a developer and distributor of uniquely engineered, nutrition-medicine products, announced the introduction of Diff-Stat™, a new supplement containing pre- and probiotics to help restore and maintain beneficial bacteria that prevent the onset of antibiotic-associated diarrhea (AAD) and clostridium difficile (C-diff).

24 Nov 2009

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

Today, Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults in various European countries.

19 Nov 2009

Universal Detection Technology to showcase its bio-weapons detection technology at Milipol Paris 2009

Universal Detection Technology, a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, announced today that it will showcase the latest developments in bio-weapons detection technology, including the TS-10-5-agent biodetection kit, with live training kit demos at Milipol Paris 2009.

11 Nov 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

A new study provides evidence that ImmunoLin®, an all natural and GRAS approved source of immunoglobulin, will provide immediate benefit to the function of the immune system and the gut. Immunoglobulins, or antibodies, are specialized proteins found in blood that the immune system naturally produces for immunity.

6 Nov 2009

Cereplast confirms that all its resins are made without the use of BPA

Cereplast, Inc., a leading manufacturer of proprietary bio-based, sustainable plastics, confirmed today that all its resins are made without the use of Bisphenol A, commonly referred to as BPA. All products made with both Cereplast resin families, including the Compostables® and the Hybrids® are BPA free.

5 Nov 2009

Mold detection device from Universal Detection Technology

Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, announced today that it is expanding its product catalogue to include a consumer-ready kit for the detection of black mold.

4 Nov 2009

Micronics inks license agreement with Biosearch Technologies

Micronics, Inc., a leading developer of point-of-care molecular diagnostic products, announced today that it has entered into a license agreement with Biosearch Technologies, Inc. (Biosearch) for the right to make, have made, use and sell Micronics’ products that incorporate Biosearch’s proprietary fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics a royalty-free use of certain of its chemistries for inclusion in Micronics’ infectious disease tests for sale in underdeveloped countries.

28 Oct 2009

Cleavage rejuvenation, Botox Breast Lift and Awake-Breast Augmentation - are they safe?

Whether their effectiveness is fact or fiction, less invasive cosmetic procedures such as cleavage rejuvenation, do-it-yourself (DIY) cosmetic therapies, and using Botox- to "lift" the breasts are making headlines, but are they safe? Plastic surgeons will discuss if these, and more, are cutting edge new discoveries or just "buyer beware" marketing hype at the American Society of Plastic Surgeons (ASPS) Plastic Surgery 2009 conference, Oct. 23 - 27, in Seattle.

24 Oct 2009

Fluorescent molecule to detect cyanide contamination in drinking water

A small molecule designed to detect cyanide in water samples works quickly, is easy to use, and glows under ultraviolet or "black" light.

22 Oct 2009

Guidelines for treating amyotrophic lateral sclerosis identified

New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Oct 2009

New guidelines for treating amyotropic lateral sclerosis

Dr. John England, Professor and Chairman of Neurology at LSU Health Sciences Center New Orleans, analyzed research findings and was responsible for the quality and accuracy of evidence analysis and the conclusions of the studies resulting in new guidelines for treating Lou Gehrig's disease, or amyotropic lateral sclerosis (ALS).

13 Oct 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009

Researchers find increase in the number of procedures performed for dermatologic health care

Researchers from Boston University School of Medicine (BUSM) and the Laser and Skin Cancer Center of Indiana, (Carmel, Indiana), found that there has been a dramatic increase in the number of procedures performed and patient demand for dermatologic health care since 2000. The findings, which were recently reported in Dermatologic Surgery, parallels the growth in the age of individuals between the ages of 40 to 55, who make up the "Baby Boomer" generation.

6 Oct 2009

Universal Detection signs deal with U.S. to become Featured U.S. Exporter of bioterrorism monitoring equipment in France

Universal Detection Technology, a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, announced today that the company has entered an agreement with U.S. Department of Commerce's Commercial Service to become a Featured U.S. Exporter (FUSE) of bioterrorism monitoring equipment in France.

6 Oct 2009

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.

6 Oct 2009

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Allergan, Inc. today filed a declaratory relief action in the United States District Court for the District of Columbia seeking a ruling that would allow Allergan to proactively share truthful and relevant information with the medical community to assist physicians in evaluating the risks and benefits of BOTOX (onabotulinumtoxinA) for certain “off-label” therapeutic uses.

5 Oct 2009

Nature's best mercury fighters: Bacteria

Mercury pollution is a persistent problem in the environment. Human activity has lead to increasingly large accumulations of the toxic chemical, especially in waterways, where fish and shellfish tend to act as sponges for the heavy metal.

5 Oct 2009

Neogen announces first-quarter results of fiscal 2010

Neogen Corporation announced today that its revenues for the first quarter of FY 2010, which ended Aug. 31, increased 12% from the previous year's first quarter to $32,347,000. First quarter net income increased 18% from the prior year's $3,733,000 to $4,395,000, or to $0.29 per share in the current year compared to the previous year's $0.25.

25 Sep 2009

Morphotek receives NIAID grant to develop human mAb therapies against staphylococcal-derived pathogens

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that it was awarded $843,289 in funding from the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to support the development of human monoclonal antibody (mAb) therapies against staphylococcal-derived toxin(s).

23 Sep 2009

Tregs to set the pace of recovery after serious lung injury

After more than 50 experiments in mice, medical scientists at Johns Hopkins have mapped out the basic steps taken by a particular set of white blood cells in setting the pace of recovery after serious lung injury.

22 Sep 2009

Toxin News and Research

Medical Nutrition launches Diff-Stat pre- and probiotic supplement to prevent the onset of AAD and C-diff

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

Universal Detection Technology to showcase its bio-weapons detection technology at Milipol Paris 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

Cereplast confirms that all its resins are made without the use of BPA

Mold detection device from Universal Detection Technology

Micronics inks license agreement with Biosearch Technologies

Cleavage rejuvenation, Botox Breast Lift and Awake-Breast Augmentation - are they safe?

Fluorescent molecule to detect cyanide contamination in drinking water

Guidelines for treating amyotrophic lateral sclerosis identified

New guidelines for treating amyotropic lateral sclerosis

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Researchers find increase in the number of procedures performed for dermatologic health care

Universal Detection signs deal with U.S. to become Featured U.S. Exporter of bioterrorism monitoring equipment in France

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Nature's best mercury fighters: Bacteria

Neogen announces first-quarter results of fiscal 2010

Morphotek receives NIAID grant to develop human mAb therapies against staphylococcal-derived pathogens

Tregs to set the pace of recovery after serious lung injury

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News